PUMA BIOTECHNOLOGY INC (PBYI) Stock Fundamental Analysis
NASDAQ:PBYI - Nasdaq - US74587V1070 - Common Stock - Currency: USD
Overall PBYI gets a fundamental rating of 5 out of 10. We evaluated PBYI against 562 industry peers in the Biotechnology industry. PBYI scores excellent on profitability, but there are some minor concerns on its financial health. PBYI is cheap, but on the other hand it scores bad on growth. These ratings could make PBYI a good candidate for value investing.
1. Profitability
1.1 Basic Checks
PBYI had positive earnings in the past year.
PBYI had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PBYI reported negative net income in multiple years.
Of the past 5 years PBYI 4 years had a positive operating cash flow.
1.2 Ratios
PBYI's Return On Assets of 14.19% is amongst the best of the industry. PBYI outperforms 96.44% of its industry peers.
PBYI has a better Return On Equity (32.87%) than 98.40% of its industry peers.
Looking at the Return On Invested Capital, with a value of 20.87%, PBYI belongs to the top of the industry, outperforming 98.22% of the companies in the same industry.
PBYI had an Average Return On Invested Capital over the past 3 years of 17.97%. This is above the industry average of 14.31%.
The last Return On Invested Capital (20.87%) for PBYI is above the 3 year average (17.97%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 32.87% | ||
| ROIC | 20.87% |
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of PBYI (13.14%) is better than 94.66% of its industry peers.
Looking at the Operating Margin, with a value of 13.44%, PBYI belongs to the top of the industry, outperforming 95.02% of the companies in the same industry.
PBYI's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 72.06%, PBYI belongs to the best of the industry, outperforming 82.21% of the companies in the same industry.
In the last couple of years the Gross Margin of PBYI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.44% | ||
| PM (TTM) | 13.14% | ||
| GM | 72.06% |
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
2. Health
2.1 Basic Checks
PBYI has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
PBYI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PBYI has been increased compared to 5 years ago.
The debt/assets ratio for PBYI has been reduced compared to a year ago.
2.2 Solvency
PBYI has an Altman-Z score of -5.97. This is a bad value and indicates that PBYI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PBYI (-5.97) is worse than 64.41% of its industry peers.
The Debt to FCF ratio of PBYI is 1.73, which is an excellent value as it means it would take PBYI, only 1.73 years of fcf income to pay off all of its debts.
PBYI has a Debt to FCF ratio of 1.73. This is amongst the best in the industry. PBYI outperforms 94.66% of its industry peers.
PBYI has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.24, PBYI is doing worse than 70.82% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for PBYI, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | 1.73 | ||
| Altman-Z | -5.97 |
ROIC/WACC1.81
WACC11.55%
2.3 Liquidity
PBYI has a Current Ratio of 1.54. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.54, PBYI is not doing good in the industry: 81.85% of the companies in the same industry are doing better.
PBYI has a Quick Ratio of 1.45. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.45, PBYI is not doing good in the industry: 82.56% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.45 |
3. Growth
3.1 Past
PBYI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 133.33%, which is quite impressive.
The Revenue has decreased by -2.19% in the past year.
The Revenue has been decreasing by -3.28% on average over the past years.
EPS 1Y (TTM)133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%5.02%
3.2 Future
Based on estimates for the next years, PBYI will show a very negative growth in Earnings Per Share. The EPS will decrease by -30.07% on average per year.
PBYI is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.09% yearly.
EPS Next Y-33.11%
EPS Next 2Y-27.19%
EPS Next 3Y-13.78%
EPS Next 5Y-30.07%
Revenue Next Year-2.74%
Revenue Next 2Y-1.59%
Revenue Next 3Y-0.56%
Revenue Next 5Y-1.09%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PBYI is valuated cheaply with a Price/Earnings ratio of 4.26.
98.58% of the companies in the same industry are more expensive than PBYI, based on the Price/Earnings ratio.
PBYI is valuated cheaply when we compare the Price/Earnings ratio to 25.05, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 10.14, the valuation of PBYI can be described as reasonable.
Based on the Price/Forward Earnings ratio, PBYI is valued cheaply inside the industry as 96.09% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of PBYI to the average of the S&P500 Index (21.07), we can say PBYI is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.26 | ||
| Fwd PE | 10.14 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PBYI indicates a rather cheap valuation: PBYI is cheaper than 99.29% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, PBYI is valued cheaply inside the industry as 99.47% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.19 | ||
| EV/EBITDA | 2.29 |
4.3 Compensation for Growth
The excellent profitability rating of PBYI may justify a higher PE ratio.
A cheap valuation may be justified as PBYI's earnings are expected to decrease with -13.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.19%
EPS Next 3Y-13.78%
5. Dividend
5.1 Amount
No dividends for PBYI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.28
+0.38 (+13.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners67.9%
Inst Owner Change11.08%
Ins Owners15.64%
Ins Owner Change3.46%
Market Cap162.79M
Analysts47.5
Price Target5.61 (71.04%)
Short Float %6.99%
Short Ratio8.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)143.52%
Min EPS beat(2)14.63%
Max EPS beat(2)272.41%
EPS beat(4)4
Avg EPS beat(4)93.44%
Min EPS beat(4)14.63%
Max EPS beat(4)272.41%
EPS beat(8)7
Avg EPS beat(8)138.48%
EPS beat(12)10
Avg EPS beat(12)235.5%
EPS beat(16)13
Avg EPS beat(16)203.66%
Revenue beat(2)2
Avg Revenue beat(2)11.04%
Min Revenue beat(2)10.36%
Max Revenue beat(2)11.71%
Revenue beat(4)4
Avg Revenue beat(4)7.5%
Min Revenue beat(4)3.3%
Max Revenue beat(4)11.71%
Revenue beat(8)6
Avg Revenue beat(8)3.61%
Revenue beat(12)9
Avg Revenue beat(12)5.25%
Revenue beat(16)11
Avg Revenue beat(16)6.03%
PT rev (1m)26.92%
PT rev (3m)26.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)17.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.26 | ||
| Fwd PE | 10.14 | ||
| P/S | 0.71 | ||
| P/FCF | 4.19 | ||
| P/OCF | 4.18 | ||
| P/B | 1.77 | ||
| P/tB | 3.97 | ||
| EV/EBITDA | 2.29 |
EPS(TTM)0.77
EY23.48%
EPS(NY)0.32
Fwd EY9.86%
FCF(TTM)0.78
FCFY23.87%
OCF(TTM)0.78
OCFY23.91%
SpS4.64
BVpS1.86
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 32.87% | ||
| ROCE | 26.42% | ||
| ROIC | 20.87% | ||
| ROICexc | 150.48% | ||
| ROICexgc | N/A | ||
| OM | 13.44% | ||
| PM (TTM) | 13.14% | ||
| GM | 72.06% | ||
| FCFM | 16.86% |
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
ROICexc(3y)84.91%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)22.75%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y271.17%
ROICexc growth 5YN/A
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
F-Score6
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | 1.73 | ||
| Debt/EBITDA | 0.51 | ||
| Cap/Depr | 0.49% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 2.88 | ||
| Cash Conversion | 91.59% | ||
| Profit Quality | 128.35% | ||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.45 | ||
| Altman-Z | -5.97 |
F-Score6
WACC11.55%
ROIC/WACC1.81
Cap/Depr(3y)62.9%
Cap/Depr(5y)77.72%
Cap/Sales(3y)2.82%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
EPS Next Y-33.11%
EPS Next 2Y-27.19%
EPS Next 3Y-13.78%
EPS Next 5Y-30.07%
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%5.02%
Revenue Next Year-2.74%
Revenue Next 2Y-1.59%
Revenue Next 3Y-0.56%
Revenue Next 5Y-1.09%
EBIT growth 1Y-6.95%
EBIT growth 3Y187.73%
EBIT growth 5YN/A
EBIT Next Year45.92%
EBIT Next 3Y3.72%
EBIT Next 5YN/A
FCF growth 1Y170.46%
FCF growth 3Y23.46%
FCF growth 5Y11.98%
OCF growth 1Y44.09%
OCF growth 3Y23.52%
OCF growth 5Y11.7%